Medical device company Teleflex (NYSE:TFX) has acquired a biomedical company with an antimicrobial technology for devices in a $30 million deal.
Semprus BioScience’s technology reduces the attachment of platelets and blood proteins at the surface of devices, according to a company statement. It closed an $18 million series B financing round in 2010 co-led by SR1, GlaxoSmithKline’s venture arm and Foundation Medical Partners, a national healthcare venture capital firm in a strategic partnership with the Cleveland Clinic. Its technology is designed to reduce hospital-acquired infections and blood clots.
The Cambridge, Massachusetts-based company was founded out of the Massachusetts Institute of Technology’s Langer Lab by David Lucchino and Dr. Christopher Loose
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Earlier this year, Teleflex got 510(k) clearance for a device to reduce complications commonly associated with epidural catheters like transient paresthesia (a sensation of tingling, pricking or numbness of a person’s skin) and inadvertent penetration of blood vessels or the dura, according to the company’s annual report.
The company’s product pipeline also includes tools to reduce microbial adhesion, deliver drugs, bind with agents in the bloodstream, or provide improved accuracy for diagnostics, according to Semprus’ website.
Last year, the Limerick, Pennsylvania company sold its aerospace and cargo business for $280 million. It also sold its marine business to an H.I.G. Capital affiliate for $121.6 million. It has been putting the proceeds from those sales to work with the latest in a series of acquisitions that have helped build the company’s medical device product line. Among its most recent acquisitions were in May for disposable catheter line EZ Blocker, which has CE Mark approval from European regulators, and catheter placement technology company VasoNovo in a $25 million deal in January 2011.
